Gapping down
Other news:
- CRBP -27.5% (announced topline results from its 28-week Phase 2b study of lenabasum in patients with cystic fibrosis; did not meet primary endpoint)
- IOVA -20.3% (pushes back timeline for BLA submission for lifileucel into 2021)
- YMAB -18.5% (receives a Refusal to File letter from FDA re its BLA for omburtamab)
- AXGT -15.1% (reports six-month follow-up for SUNRISE-PD Phase 2 trial of AXO-Lenti-PD)
- LOGI -5.8% (AAPL stops selling rival headphones, according to Bloomberg)
- AMAG -2.9% (receives notice from FDA to withdraw approval of Makena)
- NCNO -2.6% (files for 5.5 mln share common stock offering by selling shareholders)
- SONO -0.9% (AAPL stops selling rival headphones, according to Bloomberg)
Analyst comments:
- AXTI -5.6% (downgraded to Neutral from Buy at B. Riley Securities)
- BFAM -1.2% (downgraded to Market Perform from Outperform at BMO Capital Markets)
- EPR -1% (downgraded to Hold from Buy at Truist)
- PSA -0.7% (downgraded to Underperform from Mkt Perform at Raymond James)